Eribulin for Treating Locally Advanced or Metastatic Breast Cancer After One Chemotherapy Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Eribulin is a recommended treatment option for locally advanced or metastatic breast cancer (LABC/MBC) in adults whose disease has progressed after at least two chemotherapy regimens. The National Institute for Health and Care Excellence (NICE) invited the manufacturer of eribulin (Halaven(®); Eisai...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Pharmacoecon Open
Main Authors: Fleeman, Nigel, Bagust, Adrian, Duarte, Rui, Richardson, Marty, Nevitt, Sarah, Boland, Angela, Kotas, Eleanor, McEntee, Joanne, Thorp, Nicky
Formato: Artigo
Idioma:Inglês
Publicado em: Springer International Publishing 2019
Assuntos:
Review Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6710448/
https://ncbi.nlm.nih.gov/pubmed/30742256
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s41669-018-0114-z
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados